These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 19744164)

  • 1. Antifibrotic effect of angiotensin blockers in hypertensive hepatitis C patients.
    Bahde R; Kapoor S
    Liver Int; 2009 Nov; 29(10):1597; author reply 1598. PubMed ID: 19744164
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin II antagonists in patients with recurrent hepatitis C virus infection after liver transplantation.
    Cholongitas E; Vibhakorn S; Lodato F; Burroughs AK
    Liver Int; 2010 Feb; 30(2):334-5. PubMed ID: 19515217
    [No Abstract]   [Full Text] [Related]  

  • 3. [High risk arterial hypertension: the role of angiotensin II receptor blockers].
    Fomin VV; Moiseev SV; Mukhin NA
    Ter Arkh; 2007; 79(10):86-91. PubMed ID: 18154154
    [No Abstract]   [Full Text] [Related]  

  • 4. AT1-receptor blockers and ACE inhibitors: alternatives or partners?
    Ruilope LM
    Int J Clin Pract Suppl; 2000 Aug; (111):20-4. PubMed ID: 15977403
    [No Abstract]   [Full Text] [Related]  

  • 5. Pulse pressure and dual angiotensin blockade.
    Safar ME
    Am J Hypertens; 2008 Feb; 21(2):133. PubMed ID: 18268484
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin receptor blockers and cardiovascular protection: are we ONTARGET?
    Ram CV; Deedwania PC
    Am J Cardiol; 2008 Nov; 102(9):1281-3. PubMed ID: 18940307
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.
    Corey KE; Shah N; Misdraji J; Abu Dayyeh BK; Zheng H; Bhan AK; Chung RT
    Liver Int; 2009 May; 29(5):748-53. PubMed ID: 19220742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Marketing makes pressure! ACE inhibitors or AT2? We must choose...].
    Jolidon RM
    Rev Med Suisse; 2006 Oct; 2(83):2372-3; author reply 2373. PubMed ID: 17112090
    [No Abstract]   [Full Text] [Related]  

  • 11. A vaccine for hypertension.
    Ménard J
    J Hypertens; 2007 Jan; 25(1):41-6. PubMed ID: 17143170
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defibrillators.
    Lai HM; Aronow WS; Kruger A; Desai H; Amin H; Frishman WH; Cohen M; Sorbera C
    Am J Cardiol; 2008 Jul; 102(1):77-8. PubMed ID: 18572039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE inhibitors and ARBs: antihypertensive medications in CKD.
    Szromba C
    Nephrol Nurs J; 2005; 32(3):332-3. PubMed ID: 16035474
    [No Abstract]   [Full Text] [Related]  

  • 14. Going after angiotensin. An ACE inhibitor or an ARB, not both, best protects the heart.
    Harv Heart Lett; 2008 Jul; 18(11):2. PubMed ID: 18693363
    [No Abstract]   [Full Text] [Related]  

  • 15. More is less? Optimal combination therapy for adequate blood pressure lowering in hypertension.
    Kjeldsen SE; Hedner T; Narkiewicz K; Oparil S
    Blood Press; 2008; 17(3):132-3. PubMed ID: 18665471
    [No Abstract]   [Full Text] [Related]  

  • 16. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
    Abuissa H; Jones PG; Marso SP; O'Keefe JH
    J Am Coll Cardiol; 2005 Sep; 46(5):821-6. PubMed ID: 16139131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How should renin-angiotensin system blockade be applied in chronic kidney disease for optimal renal protection?
    Zhang X; Hou FF
    Chin Med J (Engl); 2007 Feb; 120(3):243-5. PubMed ID: 17355830
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.